Leading pelvic-health devices provider American Medical Systems (AMMD) has announced the global launch of MoXy Liquid Cooled Fiber, its novel therapy system for benign prostatic hyperplasia/BPH (enlarged prostate).
American Medical received 510 (k) approval from the U.S. Food and Drug Administration for MoXy Fiber in June 2010. The system is now available across the U.S., Europe and Australia. The company will continue launching MoXy Fiber in other markets throughout the remainder of 2010.
BPH, a non-cancerous enlargement of the prostate gland, afflicts as many as 14 million people in the U.S. and is prevalent in older men. The symptoms of BPH, including difficulty in starting a urine stream and frequent urination, are evident in half of all men over 50 years of age. Surgery (such as resection of the prostate and laser procedure) and drug therapy are mostly used as treatment options for this condition.
The MoXy Fiber, which has been designed for laser treatment of BPH, offers rapid and effective tissue vaporization. The system’s Active Cooling Cap technology leverages 360-degree saline flow to maintain the temperature of the fiber tip for extended fiber longevity.
American Medical expanded its BPH therapy range in May 2010 with the launch of the GreenLight XPS laser therapy system, which is built upon the proven technology and performance of the company’s GreenLight PV and HPS laser systems.
The MoXy Fiber is intended for use with GreenLight XPS. According to the company, the combination should offer 50% faster tissue vaporization than the GreenLight HPS 120 Watt system, leading to a reduction in treatment time and cost.
Minnesota-based American Medical is a world leader in manufacturing medical devices and procedures for treating health problems of both men and women. In addition to the U.S., the company sells its products in Canada , Asia, Australia , Europe and South America .
American Medical derives nearly half of its revenues from its Men’s Health business, which comprises erectile restoration, male continence and prostate treatments. Revenues from Men’s Health continue to be boosted by higher demand for the erectile restoration and male continence product lines. The company’s BPH therapy sales rose 4% year-over-year to $29.2 million in second-quarter fiscal 2010.
American Medical remains focused on rolling out new products to drive growth. Other positive factors are represented by the company’s strong position in the urology market, expanded margins and a healthy balance sheet. However, American Medical’s European markets are yet to recover from the macroeconomic headwinds. Currently, we have a Neutral rating on the stock.
AMER MED SYS (AMMD): Free Stock Analysis Report
Zacks Investment Research
